First patient recruited into Alzinova's phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer's disease

/PRNewswire/ -- Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer's disease by specifically targeting neurotoxic...

Related Keywords

Sweden ,Finland ,Stockholm ,Swedish ,Kristina Torfg ,Sahlgrenska University Hospital In Gothenburg ,Clinical Research Services Turku ,First In Human ,Sahlgrenska University Hospital ,Abuse Regulation ,Certified Advisor ,Nasdaq First North Growth Market ,Cision Ab ,